<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04694027</url>
  </required_header>
  <id_info>
    <org_study_id>Omega 3 &amp; vit E for mastalgia</org_study_id>
    <nct_id>NCT04694027</nct_id>
  </id_info>
  <brief_title>Omega-3 Fatty Acids Plus Vitamin E Cosupplementation Versus Vitamin E in Fibrocystic Breast Patient</brief_title>
  <acronym>FCC</acronym>
  <official_title>Omega-3 Fatty Acids Plus Vitamin E Cosupplementation Versus Vitamin E in Fibrocystic Breast Patient</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cairo University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cairo University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      to identify the effect of omega-3 plus vitamin E cosupplementation on mastalgia in patients&#xD;
      with FCC and to compare its effect with that of vitamin E only.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      120 patients will be enrolled in the study and divided into three groups each group consisted&#xD;
      40 patient then the severity of mastalgia in the three groups before, through and after&#xD;
      intervention. Radiological assessment was done before and after the intervention.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 2021</start_date>
  <completion_date type="Anticipated">March 2021</completion_date>
  <primary_completion_date type="Anticipated">March 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>improvement of pain severity</measure>
    <time_frame>3 months</time_frame>
    <description>improvement of pain on visual analogue scale</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>improvement of radiological finding</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Mastalgia</condition>
  <arm_group>
    <arm_group_label>group a</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>will receive omega 3 plus vitamin E</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group b</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>will receive vitamin E</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group c</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>no intervention just reassurance and analgesics on need</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Omega 3 fatty acid</intervention_name>
    <description>omega 3 1000 mg</description>
    <arm_group_label>group a</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>VitaE</intervention_name>
    <description>vitamin e 400 mg</description>
    <arm_group_label>Group b</arm_group_label>
    <arm_group_label>group a</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  all females with mastalgia aged 18 to 55&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Pregnant and lactating women, patient who had a recent breast abscess or breast drainage,&#xD;
        patient used omega-3 and vitamin E supplementation before the trial and postmenopausal&#xD;
        women.&#xD;
&#xD;
        -&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Rehab Sabry</last_name>
    <phone>0201063314476</phone>
    <email>rehab.yassen@kasralainy.edu.eg</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Heba El nahas</last_name>
    <phone>020104810684</phone>
    <email>hebagalal@kasralainy.edu.eg</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Rehab Sabry</name>
      <address>
        <city>Cairo</city>
        <state>Muslim</state>
        <zip>11231</zip>
        <country>Egypt</country>
      </address>
    </facility>
    <contact>
      <last_name>Rehab Sabry</last_name>
      <email>rehab.yassen@kasralainy.edu.eg</email>
    </contact>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>December 31, 2020</study_first_submitted>
  <study_first_submitted_qc>December 31, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 5, 2021</study_first_posted>
  <last_update_submitted>December 31, 2020</last_update_submitted>
  <last_update_submitted_qc>December 31, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Cairo University</investigator_affiliation>
    <investigator_full_name>Rehab Sabry</investigator_full_name>
    <investigator_title>assistant lecturer</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibrocystic Breast Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

